US pharma major Bristol Myers Squibb revealed it has appointed Dr Cristian Massacesi as executive vice president, chief medical officer and head of development, effective August 1, 2025. 26 July 2025
UK government-backed Cell and Gene Therapy Catapult (CGT Catapult), a tech and innovation organization specializing in the advancement of the cell and gene therapy industry, has appointed Ed Samuel as its chief operations officer (COO). 23 July 2025
After 13 years at the helm of the UK’s BioIndustry Association, Steve Bates has tendered his resignation as chief executive of the BIA to take up a newly created position announced today as executive chair for the Office of Life Science within the UK government. His last day at the BIA will be Friday, September 26, 2025. 23 July 2025
Neuraxpharm Group, a privately-held German specialty pharma focused on central nervous system (CNS) disorders, today announced the launch of a new affiliate, Neuraxpharm Australia, led by newly appointed head of commercial, Avendran Naidu, as the company continues to expand globally. 22 July 2025
NodThera, a privately-held biotech working in chronic inflammatory diseases through selective modulation of the NLRP3 inflammasome, has announced the appointment of Jyothis George as chief medical officer (CMO), effective immediately. 21 July 2025
German mRNA specialist BioNTech has announced that Ryan Richardson will step down from his position as chief strategy officer and member of the management board. 18 July 2025
Bayer is giving chief executive Bill Anderson more time to deliver on his ambitious efforts to reshape the German group, extending his contract by three years to March 2029. The move signals strong support from the company’s supervisory board, which voted unanimously in favor of the renewal. 17 July 2025
US biotech Tract Bio has appointed Chris Galloway as chief medical and development officer, as it prepares for an investigational new drug filing for its lead oncology candidate, TP-101, within the next 18 months. The Boston-based company is also expanding its board with two senior figures from the oncology and biotech world: Mark Adler and Kristiina Vuori. 15 July 2025
BrainXell, a US biotechnology company developing iPSC-based CNS disease models and regenerative cell therapies, has announced the appointment of Katherine Vega Stultz as its new chief executive and board director. 11 July 2025
French biotech Inventiva has changed up its executive team as it continues to bet on experimental MASH therapy lanifibranor, bringing in new leadership to steer the drug through its late-stage development and potential regulatory filings. 10 July 2025
Radiant Biotherapeutics, a Canadian biotech advancing multi-specific, multi-affinity antibody (Multabody) therapeutics in cancer and autoimmune diseases, has announced the appointment of Deborah Geraghty as president and chief executive. 9 July 2025
SpyBiotech, a UK biotech with a novel vaccine platform technology that can target infectious diseases, cancer and chronic diseases, has appointed Prakash Bhuyan as chief medical officer (CMO). 12 August 2024
Finland-based Faron Pharmaceuticals, a biopharma reprogramming myeloid cells to activate anti-tumor immunity in hematological and solid tumor microenvironments, has announced that its chief executive Markku Jalkanen is to retire. 7 August 2024
A change at the top is on the way at Cour Pharmaceuticals, a privately-held US biotech developing disease-modifying therapies designed to induce antigen-specific tolerance for immune-mediated diseases. 1 August 2024
German infectious disease specialist AiCuris Anti-infective Cures has announced the appointment of Cynthia Wat as chief medical officer (CMO). 30 July 2024
USA-based brain health biotech Mind Medicine (MindMed; Nasdaq: MNMD) announced the appointment of Stephanie Fagan as Chief Corporate Affairs Officer. 30 July 2024
Zymeworks has appointed Leone Patterson as executive vice president, and chief business and financial officer, effective September 1, 2024. 26 July 2024
The appointment of Dr Sicard comes at a time when the company has selected its lead candidate, DGX-01, a first-in-class recombinant protein that aims to replicate insulin-producing beta cells in t 25 July 2024
Latigo Biotherapeutics, a privately-held US biotech focused on developing non-opioid pain medicines, has appointed Nima Farzan as chief executive. 23 July 2024
Nucleome Therapeutics, a UK biotech using spatial genomics to discover precision medicines for complex diseases, has appointed Mark Bodmer as chief executive. 16 July 2024
Ophirex, a registered public benefit corporation developing an oral field treatment to address the global unmet medical needs of snakebite victims, has announced the appointment of Jeremy Gowler as chief executive. 15 July 2024